Pharmaceutical compositions and method of treatment employing 1,3-dioxo-2,2-disubstituted indanyloxy alkanoic acids
AssigneeMerck & Co., Inc.
InventorsEdward J. Cragoe, Jr., Otto W. Woltersdorf, Jr.
Life of this patent
Estimating the term…
Abstract
[1,3-Dioxo-2-substituted and 2,2-disubstituted-indanyloxy(or thio)]alkanoic acids and their salts, esters and amides are disclosed. The products display a dual pharmaceutical utility in that they exhibit diuretic, saluretic and uricosuric activity. The acid products are prepared by treating a (2- or 2,2-di)substituted-6-hydroxy-(or mercapto)-1,3-indanedione with a haloalkanoic acid or ester thereof and if the ester is employed hydrolyzing the ester.
Claims4
A pharmaceutical composition useful in the treatment of edema and hypertension which also maintains uric acid at pretreatment levels or causes a decrease in uric acid in patients which comprises along with a pharmaceutically acceptable carrier 50 mg. to 500 mg. of a compound of the formula:
- ##SPC15##
- wherein
- A is oxygen;
- R is lower alkyl having from 1 to 5 carbon atoms, cycloalkyl, phenyl or substituted phenyl wherein the substituent is lower alkyl or halo,
- R.sup.1 is hydrogen, lower alkyl having 1 to 5 carbon atoms, lower alkenyl having 3 to 5 carbon atoms, lower alkynyl having from 3 to 5 carbon atoms, phenyl lower alkyl wherein lower alkyl has 1 to 3 carbon atoms, phenyl lower alkenyl wherein lower alkenyl has 2 to 5 carbon atoms, phenyl or substituted phenyl wherein the substituent is lower alkyl or halo;
- X.sup.1 is hydrogen, methyl or halo;
- and
- X.sup.2 is methyl or halo;
- and
- Y is alkylene or haloalkylene containing a maximum of 4 carbon atoms, and
- the racemic form, the enantiomers and the non-toxic, pharmacologically acceptable salt thereof.
A method for the treatment of edema and hypertension which comprises administering to a patient in need of said treatment a unitary dosage of from 50 mg. to 500 mg. of a compound of the formula:
- ##SPC16##
- wherein
- A is oxygen;
- R is lower alkyl having from 1 to 5 carbon atoms, cycloalkyl, phenyl or substituted phenyl wherein the substituent is lower alkyl or halo;
- R.sup.1 is hydrogen, lower alkyl having 1 to 5 carbon atoms, lower alkenyl having 3 to 5 carbon atoms, lower alkynyl having from 3 to 5 carbon atoms, phenyl lower alkyl wherein lower alkyl has 1 to 3 carbon atoms, phenyl lower alkenyl wherein the lower alkenyl has 2 to 5 carbon atoms, phenyl or substituted phenyl wherein the substituent is lower alkyl or halo;
- X.sup.1 is hydrogen, methyl or halo;
- and
- X.sup.2 is methyl or halo;
- and
- Y is alkylene or haloalkylene containing a maximum of 4 carbon atoms, and
- the racemic form, the enantiomers and the non-toxic, pharmacologically acceptable salt thereof.
Dependencies are inferred from the claim text.